1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Medulloblastoma - Pipeline Review, H2 2016

Medulloblastoma - Pipeline Review, H2 2016

  • December 2016
  • -
  • Global Markets Direct
  • -
  • 95 pages

Medulloblastoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma – Pipeline Review, H2 2016, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 3 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Medulloblastoma - Pipeline Review, H2 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Medulloblastoma Overview 8
Therapeutics Development 9
Pipeline Products for Medulloblastoma - Overview 9
Pipeline Products for Medulloblastoma - Comparative Analysis 10
Medulloblastoma - Therapeutics under Development by Companies 11
Medulloblastoma - Therapeutics under Investigation by Universities/Institutes 12
Medulloblastoma - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Medulloblastoma - Products under Development by Companies 15
Medulloblastoma - Products under Investigation by Universities/Institutes 16
Medulloblastoma - Companies Involved in Therapeutics Development 17
Bayer AG 17
DelMar Pharmaceuticals Inc 18
Ignyta Inc 19
IMPACT Therapeutics Inc 20
Lipocure Ltd 21
MacroGenics Inc 22
NewLink Genetics Corp 23
Novogen Ltd 24
Progenics Pharmaceuticals Inc 25
Stemline Therapeutics Inc 26
ThromboGenics NV 27
VBI Vaccines Inc 28
Vyriad Inc 29
Medulloblastoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(topotecan hydrochloride + vincristine sulfate) - Drug Profile 40
Product Description 40
Mechanism Of Action 40
RandD Progress 40
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 41
Product Description 41
Mechanism Of Action 41
RandD Progress 41
dianhydrogalactitol - Drug Profile 42
Product Description 42
Mechanism Of Action 42
RandD Progress 42
Edotreotide Labeled Yttrium 90 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
RandD Progress 56
IMP-5471 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
RandD Progress 58
indoximod - Drug Profile 59
Product Description 59
Mechanism Of Action 59
RandD Progress 59
irinotecan hydrochloride + TBio-02 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
RandD Progress 64
Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile 65
Product Description 65
Mechanism Of Action 65
RandD Progress 65
Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile 66
Product Description 66
Mechanism Of Action 66
RandD Progress 66
nifurtimox - Drug Profile 67
Product Description 67
Mechanism Of Action 67
RandD Progress 67
nifurtimox SR - Drug Profile 68
Product Description 68
Mechanism Of Action 68
RandD Progress 68
Oncolytic Virus to Target CD46 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile 69
Product Description 69
Mechanism Of Action 69
RandD Progress 69
p28 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
RandD Progress 70
pyrvinium pamoate - Drug Profile 72
Product Description 72
Mechanism Of Action 72
RandD Progress 72
SL-301 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
RandD Progress 73
Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile 74
Product Description 74
Mechanism Of Action 74
RandD Progress 74
taladegib - Drug Profile 75
Product Description 75
Mechanism Of Action 75
RandD Progress 75
THR-317 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
RandD Progress 77
Trilexium - Drug Profile 80
Product Description 80
Mechanism Of Action 80
RandD Progress 80
VBI-1901 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
RandD Progress 82
Vimo-101 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
RandD Progress 84
VMY-1103 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
RandD Progress 85
Medulloblastoma - Dormant Projects 86
Medulloblastoma - Product Development Milestones 87
Featured News and Press Releases 87
Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 87
Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations 87
Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 88
Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 89
Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 89
Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083 90
Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant 91
Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors 91
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 94
Disclaimer 95

List of Tables
Number of Products under Development for Medulloblastoma, H2 2016 9
Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Medulloblastoma - Pipeline by Bayer AG, H2 2016 17
Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2016 18
Medulloblastoma - Pipeline by Ignyta Inc, H2 2016 19
Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H2 2016 20
Medulloblastoma - Pipeline by Lipocure Ltd, H2 2016 21
Medulloblastoma - Pipeline by MacroGenics Inc, H2 2016 22
Medulloblastoma - Pipeline by NewLink Genetics Corp, H2 2016 23
Medulloblastoma - Pipeline by Novogen Ltd, H2 2016 24
Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 25
Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H2 2016 26
Medulloblastoma - Pipeline by ThromboGenics NV, H2 2016 27
Medulloblastoma - Pipeline by VBI Vaccines Inc, H2 2016 28
Medulloblastoma - Pipeline by Vyriad Inc, H2 2016 29
Assessment by Monotherapy Products, H2 2016 30
Assessment by Combination Products, H2 2016 31
Number of Products by Stage and Target, H2 2016 33
Number of Products by Stage and Mechanism of Action, H2 2016 35
Number of Products by Stage and Route of Administration, H2 2016 37
Number of Products by Stage and Molecule Type, H2 2016 39
Medulloblastoma - Dormant Projects, H2 2016 86

List of Figures
Number of Products under Development for Medulloblastoma, H2 2016 9
Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 30
Number of Products by Top 10 Targets, H2 2016 32
Number of Products by Stage and Top 10 Targets, H2 2016 32
Number of Products by Top 10 Mechanism of Actions, H2 2016 34
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34
Number of Products by Routes of Administration, H2 2016 36
Number of Products by Stage and Routes of Administration, H2 2016 36
Number of Products by Molecule Types, H2 2016 38
Number of Products by Stage and Molecule Types, H2 2016 38

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase CSK (C Src Kinase ...

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

  • $ 2500
  • Company report
  • December 2016
  • by Global Markets Direct

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme (GBM) – Pipeline Review, ...

Gliosarcoma - Pipeline Review, H2 2016

Gliosarcoma - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Gliosarcoma - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gliosarcoma – Pipeline Review, H2 2016, provides an overview of the ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.